Prelude Therapeutics Incorporated
NASDAQ: PRLD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Krishna Vaddi
- Employees
- 131
- Headquarters
- Wilmington, United States
- IPO year
- 2020
- Market cap
- $243.1M
- Website
- https://www.preludetx.com
Loading PRLD…
Loading profile data…Frequently asked questions about PRLD
What does Prelude Therapeutics Incorporated (PRLD) do?
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, P...
Where does PRLD trade?
Prelude Therapeutics Incorporated (PRLD) trades on the NASDAQ Global Select.
What sector is PRLD in?
Prelude Therapeutics Incorporated (PRLD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Prelude Therapeutics Incorporated?
Krishna Vaddi is the chief executive officer of Prelude Therapeutics Incorporated (PRLD).
Where is Prelude Therapeutics Incorporated headquartered?
Prelude Therapeutics Incorporated is headquartered in United States.
Does PRLD pay a dividend?
Prelude Therapeutics Incorporated (PRLD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRLD go public?
Prelude Therapeutics Incorporated (PRLD) completed its initial public offering in 2020.